Advertisement
Advertisement
PRE
Prenetics Global Limited Class A Ordinary Share
19.10
USDSponsored
+1.39
+7.85%
Feb 06, 15:58 UTC -5
Closed
After-Market
19.10
0.00
0.00%
PRE Earnings Reports
Positive Surprise Ratio
PRE beat 6 of 12 last estimates.
50%
Next Report
Date of Next Report
Mar 09, 2026
Estimate for Q4 25 (Revenue/ EPS)
$38.68M
/$0.04
Implied change from Q3 25 (Revenue/ EPS)
+64.22%
/-107.55%
Implied change from Q4 24 (Revenue/ EPS)
+268.83%
/-103.13%
Prenetics Global Limited Class A Ordinary Share earnings per share and revenue
On Nov 10, 2025, PRE reported earnings of -0.53 USD per share (EPS) for Q3 25, beating the estimate of -0.55 USD, resulting in a 4.59% surprise. Revenue reached 23.55 million, compared to an expected 26.26 million, with a -10.30% difference. The market reacted with a -3.65% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 2 analysts forecast an EPS of 0.04 USD, with revenue projected to reach 38.68 million USD, implying an decrease of -107.55% EPS, and increase of 64.22% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
Adaptive Biotechnologies Corporation Common Stock
Report Date
Feb 05, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.09
Surprise
+51.33%
FAQ
What were Prenetics Global Limited Class A Ordinary Share's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Prenetics Global Limited Class A Ordinary Share reported EPS of -$0.53, beating estimates by 4.59%, and revenue of $23.55M, -10.3% below expectations.
How did the market react to Prenetics Global Limited Class A Ordinary Share's Q3 2025 earnings?
The stock price moved down -3.65%, changed from $12.34 before the earnings release to $11.89 the day after.
When is Prenetics Global Limited Class A Ordinary Share expected to report next?
The next earning report is scheduled for Mar 09, 2026.
What are the forecasts for Prenetics Global Limited Class A Ordinary Share's next earnings report?
Based on 2
analysts, Prenetics Global Limited Class A Ordinary Share is expected to report EPS of $0.04 and revenue of $38.68M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement